Medical Innovation: Equillium's Itolizumab Delivers Promising Results in Phase 2 Trial

Unknown Apr 02, 2026 1 Views

Equillium Inc.'s itolizumab has demonstrated significant potential in treating moderate to severe ulcerative colitis. In a recent Phase 2 study, the drug achieved a 16.7% endoscopic remission rate, matching the performance of adalimumab, a widely used biologic treatment. The study also reveal...

Stay Ahead – Explore Now! Tata Mumbai Marathon 2026 To Host Record 69,100 Runners